QSI
Quantum-Si incorporated
NASDAQ · Healthcare · Biotechnology · US
$0.77
+0.66%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.6M | 2.4M | 3.1M | 1.1M | — |
| Cost of Revenue | 1.0M | 1.3M | 1.5M | 594.0K | — |
| Gross Profit | 562.0K | 1.2M | 1.6M | 488.0K | — |
| Operating Expenses | |||||
| R&D Expense | 55.1M | 53.8M | 59.6M | 67.0M | 72.1M |
| SG&A Expense | 40.6M | 44.8M | 50.5M | 44.6M | 42.3M |
| General & Admin Expense | 10.0M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | 9.5M |
| Total Operating Expenses | 95.7M | 98.5M | 110.2M | 111.7M | 123.8M |
| Cost and Expenses | 96.8M | 99.8M | 111.6M | 112.3M | 123.8M |
| Operating Income (EBIT) | (95.2M) | (97.4M) | (108.6M) | (111.2M) | (123.8M) |
| Non-Operating | |||||
| Interest Income | 3.4M | 9.0M | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 3.4M | 9.0M | — | — | — |
| Other Non-Op Income/Expense | (3.4M) | (3.9M) | 7.6M | 15.2M | (8.6M) |
| Non-Operating Income (excl Interest) | 437.0K | — | (7.6M) | (15.2M) | (9.5M) |
| EBT (Pre-Tax Income) | (98.6M) | (101.3M) | (101.0M) | (96.0M) | (132.4M) |
| Income Tax Expense | (95.0K) | 58.0K | 56.0K | — | — |
| Bottom Line | |||||
| Net Income | (98.5M) | (101.3M) | (101.0M) | (96.0M) | (132.4M) |
| Earnings from Cont. Ops | (98.5M) | (101.3M) | (101.0M) | (96.0M) | (132.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (98.5M) | (101.3M) | (101.0M) | (96.0M) | (132.4M) |
| Per Share | |||||
| Basic EPS | ($0.46) | ($0.51) | ($0.71) | ($0.68) | ($0.95) |
| Diluted EPS | ($0.46) | ($0.51) | ($0.71) | ($0.68) | ($0.95) |
| Revenue Per Share | $0.01 | $0.01 | $0.02 | $0.01 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 217.8M | 197.8M | 143.2M | 141.3M | 139.3M |
| Diluted Shares Outstanding | 217.8M | 197.8M | 143.2M | 141.3M | 139.3M |
| Profitability Metrics | |||||
| EBITDA | (92.0M) | (92.9M) | (96.4M) | (91.8M) | (111.8M) |
| D&A | 3.6M | 4.5M | 4.6M | 4.2M | 2.6M |
| EBIT | (95.6M) | (97.4M) | (101.0M) | (96.0M) | (114.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026